Technologies

Affimed’s technologies have the potential to provide
a quantum leap in clinical benefit for critically ill 
cancer patients.

 
 
     
 
  NK-Cell TandAbs, T-Cell TandAbs and Trispecific Abs  
   
 
Monoclonal antibodies (mAbs) are large proteins that bind with high affinity and precision to a biological target (such as a tumor-associated antigen). They have become a well-validated and established treatment option for a variety of diseases. Next-generation antibody therapeutics are designed to improve on mAbs by incorporating additional features, such as improved effector function or dual binding to two different antigens or epitopes. Affimed develops TandAbs and Trispecific Abs for substantially increasing the efficacy, specificity and/or extend the therapeutic window of current therapeutics.  
The company has three proprietary platforms:
  NK-cell TandAbs – tetravalent, bifunctional proteins that recognize a specific biologic target and, utilizing their second functionality, bind with high affinity to NK cells and thereby direct the NK-cells to eliminate the target cell.
     
  T-cell TandAbs – tetravalent, bifunctional proteins that recognize a specific biologic target and utilizing their second functionality, bind with high affinity to T-cells and thereby direct the T-cell to eliminate the target cell.
     
  Trispecific Abs for dual targeting of tumor cells – trifunctional structures that can be designed to target two different targets/epitopes on the tumor cell and with the third functionality bind with high affinity to either T-cells or NK-cells.
 
     
 
Affimed's Antibody Technologies
 
Download Paper
 
     
 
 
 
  Affimed has published a paper on its proprietary technology platform:
Weichel, M. et al., European Pharmaceutical Review, 2015, Vol. 20/1, p.27-32
 
 
 
 
  Impressum Disclaimer